Replies to post #260211 on Avid Bioservices Inc (CDMO)

[volgoat]

Plus it's always tougher to develop combination therapy than monotherapy especially one has little to no single agent activity.

Yep, will take years to find doses and schedules and may not even be safe together, need a lot of money for all that....

Or a partner and with 300 m shares and all retail, you can bet a 1/20 or 1/25 RS comes b4 a partner, BP is not in the business of making retail shareholders rich off a penny stock....

If a deal comes, longs will be so diluted by then it is a moot point, but the boys will reap all those fat and juicy BP stock rights and keep their big salaries.

Retail has been played and fleeced........at least the longs that have been here for more than 6 months and the ones here for years are going to be exponentially worse off..

[swg_tdr]

jq1234, IMPRESSIVE ARGUMENT, detail please
\
on

For the record, the longest published mOS in 2nd line NSCLC trial with docetaxel I saw was 22 months.

thanks
best,
N

[thealias2002]

Question; I remember seeing Indian treatment centers reporting much higher/better figures than other sites in the p2 trial data. Is this why?? The Asian/lack of stratification theory?